Table 1 Overview of samples included in GWAS meta-analysis of OUD cases vs. OUD controls.

From: Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci

Cohorts

EUR cases

EUR controls

EUR Neffective

AFR cases

AFR Controls

AFR Neffective

Case definition

Control definitiona

MVP 1-2 combined

8529

267,737

33,062

4032

71,511

15,265

ICD-9/ICD-10

unscreened

MVP Release 1

6367

202,636

24,692

3151

54,178

11,911

  

MVP Release 2

2162

65,101

8370

881

17,333

3354

  

PGC-SUDb

3272

25,437

11,596

1231

7063

4193

DSM-IV

unexposed

Partners Biobank

1039

20,271

3953

-

-

-

ICD-9/ICD-10

no SUD diagnosis

BioVU

933

3,732

2,986

-

-

-

ICD-9/ICD-10

unscreened

FinnGen

651

214,999

2596

-

-

-

ICD-9/ICD-10

unscreened

Yale-Penn 3

448

1538

1388

172

868

574

DSM-IV

no OUD diagnosis

iPSYCH

379

5221

1413

-

-

-

ICD-9/ICD-10

no OUD diagnosis

Ancestry-specific subtotals

15251

538,935

56,994

5435

79,442

20,032

  

Overall total cases

20,686

       

Overall total controls

618,377

       

Overall total N

639,063

Total Neffective

77,026

     

EUR total N

554,186

EUR Neffective

56,994

     

AFR total N

84,877

AFR Neffective

20,032

     
  1. aControl definition: “no OUD diagnosis”—controls assessed for OUD and not diagnosed. “Unscreened”—controls not assessed for OUD and thus may have unassessed opioid-related problems.bThe PGC-SUD OUD analysis included AFR and EUR participants from Yale-Penn 1 (N = 3922; Ncases = 1656) and Yale-Penn 2 (N = 2483; Ncases = 846)—data from Yale-Penn supplied 67.4% of AFR cases and 51.1% of EUR cases for the overall PGC-SUD meta-analysis. Yale-Penn 3 is included as a separate cohort in the current analysis. Effective sample size was calculated as: Neffective = 4/[(1/ncase) + (1/ncontrol)].